Publications by authors named "Michael O Falster"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

942

Total Likes

3

Extended Reach

9,624

Social Features

75
P
Polypharmacy among older Australians, 2006-2017: a population-based study.
Amy T Page, Michael O Falster, Melisa Litchfield, Sallie-Anne Pearson, Christopher Etherton-Beer

Med J Aust· July 2019

Videos about Article: user user

2 2 73 2 18 2

View All Article and Social Media Activity
P
Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset.
Hannah Wallace, James Wick, Brendon L Neuen, Luke Buizen, Sunil V Badve, Michael O Falster

Diabetes Obes Metab· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of follow-up testing of abnormal eGFR and UACR for the detection of chronic kidney disease in Australian primary care: analysis of a national general practice dataset.
Angela Kathy Li, Sradha Kotwal, Hannah Wallace, Daniel Bekele Ketema, James Wick, Michael O Falster

BMJ Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia.
Hans Kristian Råket, Tamara Milder, Melisa Litchfield, Camilla Bjørn Jensen, Joanna Nan Wang, Michael O Falster

Clin Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Variation in uptake of sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor analogues in adults with type 2 diabetes at high cardiovascular risk.
Juliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, Alys Havard, Jerry R Greenfield, Michael O Falster

Eur J Clin Pharmacol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in use of sodium-glucose cotransporter 2 inhibitors among people with type 2 diabetes following hospitalisation with heart failure: A population-based study.
Jialing Lin, Tamara Y Milder, Claire T Deakin, Juliana de Oliveira Costa, Alys Havard, Michael O Falster

Diabetes Res Clin Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-discharge pharmacotherapy in people with atrial fibrillation hospitalized for acute myocardial infarction: an Australian cohort study 2018-22.
Claire T Deakin, Juliana de Oliveira Costa, David Brieger, Jialing Lin, Andrea L Schaffer, Michael O Falster

Eur Heart J Qual Care Clin Outcomes· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the burden of diabetes in Australia underestimated? Comparison of diabetes ascertainment using linked administrative health data and an Australian diabetes registry.
Emma Cox, Joanne Gale, Michael O Falster, Juliana de Oliveira Costa, Stephen Colagiuri

Diabetes Res Clin Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of SGLT2i in people with type 2 diabetes following hospitalisation for heart failure: A cause for concern?
Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, Juliana de Oliveira Costa, Brendon L Neuen, Michael O Falster

Diabetes Obes Metab· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022.
Tamara Y Milder, Jialing Lin, Sallie-Anne Pearson, Jerry R Greenfield, Richard O Day, Michael O Falster

Br J Clin Pharmacol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trajectories of Opioid Use Before and After Cancer Diagnosis: A Population-Based Cohort Study.
Benjamin Daniels, Tim Luckett, Winston Liauw, Michael O Falster, Natasa Gisev

J Pain Symptom Manage· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prescription and dispensing duration of medicines for hypertension and other chronic conditions: a review of international policies and evidence to inform the Australian setting.
Peder Af Geijerstam, Michael O Falster, John Chalmers, Andrew J McLachlan, Anthony Rodgers

Hypertens Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Medicines Intelligence Data Platform: A Population-Based Data Resource From New South Wales, Australia.
Helga Zoega, Michael O Falster, Malcolm B Gillies, Melisa Litchfield, Ximena Camacho

Pharmacoepidemiol Drug Saf· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
Juliana de Oliveira Costa, Jialing Lin, Tamara Y Milder, Jerry R Greenfield, Richard O Day, Michael O Falster

Diabetes Obes Metab· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of coordinated care on adherence to antihypertensive medicines among adults experiencing polypharmacy in Australia.
Jialing Lin, Juliana de Oliveira Costa, Sallie-Anne Pearson, Nicholas A Buckley, David Brieger, Michael O Falster

J Hypertens· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Australian Health Care Homes trial: quality of care and patient outcomes. A propensity score-matched cohort study.
Duong T Tran, Michael O Falster, Jim Pearse, Deniza Mazevska, Patrick McElduff

Med J Aust· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
ution of the data and methods in real-world COVID-19 vaccine effectiveness studies on mortality: a oping eview protocol.
Paulina Stehlik, Caroline Dowsett, Ximena Camacho, Michael O Falster, Renly Lim

BMJ Open· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
Brendon L Neuen, Hiddo J L Heerspink, Priya Vart, Brian L Claggett, Robert A Fletcher, Michael O Falster

Circulation· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-hospital outcomes by insurance type among patients undergoing percutaneous coronary interventions for acute myocardial infarction in New South Wales public hospitals.
Juliana de Oliveira Costa, Sallie-Anne Pearson, David Brieger, Sanja Lujic, Md Shajedur Rahman Shawon, Michael O Falster

Int J Equity Health· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Mortality and Reintervention After Endovascular and Open Abdominal Aortic Aneurysm Repairs in Australia, Germany, and the United States.
Jialin Mao, Christian-Alexander Behrendt, Michael O Falster, Ramon L Varcoe, Xinyan Zheng

Ann Surg· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
Jialing Lin, Sallie-Anne Pearson, Jerry R Greenfield, Kyeong Hye Park, Alys Havard, Michael O Falster

Eur J Clin Pharmacol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence and Adherence to Cardiovascular Medicines in Australia.
Juliana de Oliveira Costa, Jialing Lin, Sallie-Anne Pearson, Nicholas A Buckley, Andrea L Schaffer, Michael O Falster

J Am Heart Assoc· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effect of varenicline and nicotine patches on preventing repeat cardiovascular events.
Annelies L Robijn, Kristian B Filion, Mark Woodward, Benjumin Hsu, Clara K Chow, Michael O Falster

Heart· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Editor's Choice - Comparison of Outcomes for Major Contemporary Endograft Devices Used for Endovascular Repair of Intact Abdominal Aortic Aneurysms.
Michael O Falster, Sarah K Garland, Louisa R Jorm, C Barry Beiles, Anthony J Freeman

Eur J Vasc Endovasc Surg· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends and Outcomes for Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in New South Wales from 2008 to 2019.
Md Shajedur Rahman Shawon, Michael O Falster, Benjumin Hsu, Jennifer Yu, Sze-Yuan Ooi

Am J Cardiol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A nationwide study of multimedicine use in people treated with cardiovascular medicines in Australia.
Andrea L Schaffer, Joel Chia, Jonathan Brett, Sallie-Anne Pearson, Michael O Falster

Pharmacotherapy· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis